Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b tarlatamab combinations in first-line extensive-stage small cell lung cancer
NL-OMON53561Phase 1Not yet recruiting
- Sponsor
- Amgen
- Start
- Jan 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of tarlatamab in small cell lung cancer (SCLC) (4 arms), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities, Treatment-related adverse events and 4 more. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON53561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53561.